Featured Research Search Results

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone or Darolutamide (TALENT)

Clinicaltrials.gov identifier:
NCT06844383

Treatment
Phase 2 study for metastatic castration-resistant prostate cancer with an HRR mutation

Research Study on the Genetics of Breast Cancer

Clinicaltrials.gov identifier:
NCT06773897

Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States

IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer

Clinicaltrials.gov identifier:
NCT07318363

Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested

Understanding Risk Factors for Stomach Cancer in People with Inherited Mutations

Surveys, Registries, Interviews
Online survey on stomach cancer risk for people with an inherited mutation in genes that are linked to an increased risk of certain cancers

Family Study for People with Certain Rare BRCA1 or BRCA2 Variants

Surveys, Registries, Interviews
Family study for adults with a known rare BRCA1 or BRCA2 variant in themselves or a relative

Testing a Targeted Therapy ETX-19477 to Treat Advanced Solid Tumors in People with a BRCA2 Mutation (ERADIC8)

Clinicaltrials.gov identifier:
NCT06395519

Treatment
Phase 1/2 treatment study for people with advanced breast, colorectal, endometrial, ovarian or pancreatic cancer

Evaluating the Safety of Nipple Sparing Mastectomy in Women With a High Risk for Breast Cancer

Clinicaltrials.gov identifier:
NCT06888388

Prevention
Study for people considering double mastectomy to reduce breast cancer risk

Vaccine for People at High Risk for Pancreatic Cancer

Clinicaltrials.gov identifier:
NCT05013216

Prevention
Phase 1 pancreatic cancer prevention study for people at high risk

A Study of Fallopian Tube Removal with Delayed Ovary Removal to Lower Ovarian Cancer Risk (TUBA-WISP-II)

Clinicaltrials.gov identifier:
NCT04294927

Prevention
Prevention study for women at high risk for ovarian cancer

Using a Shorter Type of MRI as a Screening Tool for People at High Risk for Prostate Cancer

Clinicaltrials.gov identifier:
NCT05384535

Prevention
Screening for people at high risk for prostate cancer

Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05932862

Treatment
Treatment study for people with advanced solid tumors

Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer with a BRCA Mutation or a Biomarker Called HRD

Clinicaltrials.gov identifier:
NCT06580314

Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD

A Study of the PARP Inhibitor Saruparib Added to Standard Treatment for High Risk BRCA-Positive Prostate Cancer

Clinicaltrials.gov identifier:
NCT06952803

Treatment
Phase 3 treatment study for BRCA-positive high-risk prostate cancer

A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with Inherited or Tumor Mutations

Clinicaltrials.gov identifier:
NCT04890613

Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer

Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)

Clinicaltrials.gov identifier:
NCT06380751

Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

Clinicaltrials.gov identifier:
NCT04251052

Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries

Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug Combined with Olaparib

Clinicaltrials.gov identifier:
NCT06488378

Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation

Pancreatic Cancer Screening Study (CAPS5)

Clinicaltrials.gov identifier:
NCT02000089

Prevention
Screening study for people at high risk for pancreatic cancer